First Trust Advisors LP Buys Shares of 422,038 ARS Pharmaceuticals, Inc. $SPRY

First Trust Advisors LP purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the first quarter, HoldingsChannel.com reports. The fund purchased 422,038 shares of the company’s stock, valued at approximately $3,389,000.

Other large investors have also recently made changes to their positions in the company. Investment Management Associates Inc. ADV raised its holdings in shares of ARS Pharmaceuticals by 15.3% during the first quarter. Investment Management Associates Inc. ADV now owns 359,074 shares of the company’s stock valued at $2,883,000 after purchasing an additional 47,571 shares during the last quarter. Bessemer Group Inc. boosted its holdings in ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after purchasing an additional 7,290 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in ARS Pharmaceuticals by 46.1% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 31,568 shares of the company’s stock worth $253,000 after purchasing an additional 9,954 shares during the period. General American Investors Co. Inc. grew its position in ARS Pharmaceuticals by 29.9% in the 1st quarter. General American Investors Co. Inc. now owns 727,154 shares of the company’s stock worth $5,839,000 after purchasing an additional 167,195 shares during the period. Finally, Kestra Advisory Services LLC raised its stake in ARS Pharmaceuticals by 1,079.3% during the 1st quarter. Kestra Advisory Services LLC now owns 40,920 shares of the company’s stock valued at $329,000 after buying an additional 37,450 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

Key ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Several law firms announced or promoted a securities class action covering investors who purchased SPRY shares between March 9 and June 24, 2026. The complaints allege ARS Pharmaceuticals made misleading statements or failed to disclose risks related to the timing of expanded CVS Caremark insurance coverage for neffy. SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
• Negative Sentiment: The allegations center on a missed July 1, 2026 CVS Caremark formulary-coverage timeline, reportedly delayed until January 2027. Investors and analysts viewed the delay as a negative surprise because broader coverage could be important to neffy’s adoption and revenue growth. A lead-plaintiff deadline of October 5, 2026 has been announced. SPRY Investor Alert
• Neutral Sentiment: ARS Pharmaceuticals is expected to report quarterly results Thursday. Investors will likely focus on neffy sales, commercial progress, cash resources and management’s explanation of the CVS Caremark timing. ARS Pharmaceuticals Expected to Post Earnings

ARS Pharmaceuticals Trading Up 3.5%

NASDAQ:SPRY opened at $5.55 on Friday. The company has a debt-to-equity ratio of 2.79, a current ratio of 4.94 and a quick ratio of 4.77. The firm has a market capitalization of $551.13 million, a price-to-earnings ratio of -2.76 and a beta of 0.98. ARS Pharmaceuticals, Inc. has a one year low of $4.91 and a one year high of $18.00. The business has a fifty day moving average price of $7.94 and a 200-day moving average price of $8.48.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. The company had revenue of $22.68 million for the quarter, compared to analysts’ expectations of $22.20 million. Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Leerink Partners lowered their price target on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, June 25th. Northland Securities initiated coverage on ARS Pharmaceuticals in a research report on Thursday, April 9th. They set an “outperform” rating and a $25.00 price objective for the company. Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Cantor Fitzgerald boosted their price target on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Finally, Wall Street Zen raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Insider Activity

In related news, insider Eric Karas sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 12,176 shares in the company, valued at approximately $121,760. The trade was a 67.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $33,550.00. Following the completion of the sale, the insider directly owned 90,910 shares of the company’s stock, valued at $909,100. This represents a 3.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.